卡铂-紫杉醇-贝伐珠单抗(CPB)后中间性肿瘤细胞减灭术(IDS)的可行性与结局:MITO-16A-MaNGO OV2A 4期试验亚组分析
该研究为 MITO-16A-MaNGO OV2A 4期试验的亚组分析,评估一线卡铂-紫杉醇-贝伐珠单抗方案后行中间性肿瘤细胞减灭术的可行性与结局。79例(20%)患者接受了IDS,其中74例在IDS前至少接受过一次贝伐珠单抗给药。中位年龄61.2岁,70%为FIGO IIIC期。IDS前化疗和贝伐珠单抗的中位周期数均为3。64例(86.5%)达到残留病灶≤1cm。术后4%患者出现发热,4%需要输血。作者结论认为含贝伐珠单抗方案未妨碍IDS,围手术期并发症发生率与不含贝伐珠单抗的预期相似。
要点
- 79例(20%)患者接受IDS,其中74例在IDS前至少接受过一次贝伐珠单抗。
- IDS前化疗和贝伐珠单抗的中位周期数均为3,64例(86.5%)达到残留病灶≤1cm。
- 术后4%患者出现发热,4%需要输血;手术伤口感染和/或裂开、盆腔脓肿、肠道不全梗阻和瘘各1例。
核心结论
- 在MITO16A-MaNGO OV2A 4期试验中,化疗联合贝伐珠单抗未妨碍IDS,围手术期并发症发生率与不含贝伐珠单抗的预期相似。
- 这些数据支持以下假设:对于计划行IDS的患者,一线化疗中添加贝伐珠单抗可能不应被拒绝。
研究设计与样本
- MITO 16A-MaNGO OV2A 4期试验的亚组分析,评估一线CPB在类临床实践 setting 中的结局。
- 400例初治上皮性卵巢癌患者,年龄≥18岁,ECOG PS 0-2,接受C(AUC 5 d1,q21)加P(175mg/m2 d1,q21)和B(15mg/kg d1 q21)共6周期,随后B维持至第22周期。
- 本报告为在新辅助治疗或次优初次手术后接受IDS的患者亚组结果。
主要发现
- 79例患者(20%)接受了IDS,其中74例在IDS前至少接受过一次贝伐珠单抗给药。
- 中位年龄61.2岁,70%的患者为FIGO IIIC期疾病。
- IDS前化疗和贝伐珠单抗的中位周期数分别为3。
- 64例患者(86.5%)达到残留病灶≤1cm。
- 术后4%的患者出现发热,4%需要输血;手术伤口感染和/或裂开、盆腔脓肿、肠道不全梗阻和瘘各1例患者。
临床怎么用
- 作者结论认为,化疗联合贝伐珠单抗未妨碍IDS,围手术期并发症发生率与不含贝伐珠单抗的预期相似。
- 作者认为这些数据支持以下假设:对于计划行IDS的患者,一线化疗中添加贝伐珠单抗可能不应被拒绝。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. METHODS: 400 chemonaïve epithelial ovarian cancer patients, age≥18, ECOG PS 0-2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd. RESULTS: 79 patients (20%) underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease ≤1cm was achieved in 64 patients (86.5%). Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. CONCLUSIONS: In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.
引用
- Daniele G, Lorusso D, Scambia G, et al. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol. 2016. PMID: 27993479. doi:10.1016/j.ygyno.2016.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。